Silk Road Medical (Nasdaq:SILK) + today filed with the SEC to confirm the expiration of an antitrust waiting period for its merger with Boston Scientific (NYSE: BSX) + .

In June, Boston Scientific announced that it agreed to acquire Silk Road Medical in a deal worth approximately $1.16 billion. Sunnyvale, California-based Silk Road Medical develops products designed to prevent stroke in patients with carotid artery disease. The technology is used in a minimally invasive procedure called transcarotid artery revascularization (TCAR).

However, last month, Boston Scientific voluntarily withdrew its premerger notification and report form. This aimed to give the U.S. Federal Trade Commission (FTC) more time to review the proposed acquisition. Meanwhile, Boston Scientific also faced FTC scrutiny over its proposed acquisition of Axonics, which remains ongoing.

Silk Road Medical said today that its stockholders voted to adopt the merger agreement at a special meeting on Sept. 5. Completion is conditioned upon, among other things, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) of 1976.

On Sept. 12, the applicable waiting period under the HSR Act expired at 11:59 p.m. ET, according to the SEC Form 8-K.